Biotech Values

[ghmm]

NKTR / PD-1/PD-L1 / NSCLC

For what its worth a couple of the docs on the call said they didn't believe there was much difference between PD-1's (don't recall if it was a general question or specific indication) but one said he believed PD-1's are a little bit better then PD-L1.

I am curious to see the PROPEL results to see if there is any difference in combo with 214 its fewer indications then PIVOT but even with the cross trial caveats, it should still provide some interesting comp's. I just wonder how much Nektar will REVEAL (little joke lets see who gets it).

On NSCLC I disagree with Dew I think the strategy changed but they will still pursue some segments just with a different strategy. They had previously mentioned PIVOT being expanded to have a few triplets (to include Ipi) and one would be in NSCLC. I tweeted this link which points to recent changes to the clinicaltrials.gov record
https://twitter.com/MauriceOnTW/status/1003724103654756352 or go directly via
https://clinicaltrials.gov/ct2/history/NCT02983045?A=7&B=8&C=Side-by-Side#StudyPageTop

Miljenko argued about competing on price

Triplet (NSCLC) may not be right strategy, little added benefit while tox issue in rise. I would prefer: define population where double (214 + Nivo) work in synergy and argue with PRICE and TREATMENT COST! $NKTR

— Miljenko Zuanic (@Miljenkoz) June 4, 2018

I wonder if they would consider doing Nivo+214+Chemo to try to one-up Merck?